Faculté de médecine, Université de Lyon, Lyon, France.
Emergency Department, CHR Metz-Thionville, Metz, France.
BMJ Open. 2022 Dec 7;12(12):e062278. doi: 10.1136/bmjopen-2022-062278.
Anterior shoulder dislocation is a common reason for consultation at the emergency department (ED). Hypnosis could be a safe and effective alternative therapy for pain relief during shoulder dislocation reduction but nowadays, evidence is not sufficient. The main objective of this study is to show that reduction under hypnosis is associated with a decrease in the use of analgesic compared with usual care.
We will conduct an interventional, controlled, multicentre, randomised study. A total of 44 patients with shoulder dislocation will be randomised in two groups: the hypnosis group (N=22) and the usual care group (N=22). The primary endpoint will be the comparison of morphine equivalent analgesic consumption during a shoulder dislocation reduction manoeuvre. Secondary endpoints will include haemodynamic parameters monitoring, patient and practitioner satisfaction using a Likert scale, use of coanalgesic or sedative drugs, number of reduction attempts and time spent at ED. Adverse events will be recorded. Statistical analysis will include parametric tests, multivariate linear regression and descriptive statistics.
This study has received ethics approval from the Comité de Protection des Personnes of Sud-Est IV on 03/11/2021 (ANSM informed on 19 November 2021). The results will be published in scientific articles and communicated in national and international conferences.
ClinicalTrial.gov: NCT04992598; National Clinical trial no ID RCB : 2021-A01382-39.
肩关节前脱位是急诊科就诊的常见原因。催眠可能是缓解肩关节脱位复位时疼痛的一种安全有效的替代疗法,但目前证据还不够充分。本研究的主要目的是证明在催眠下复位与常规护理相比,镇痛剂的使用量减少。
我们将进行一项干预性、对照性、多中心、随机研究。共有 44 例肩关节脱位患者将被随机分为两组:催眠组(N=22)和常规护理组(N=22)。主要终点将是比较在肩关节脱位复位操作过程中吗啡等效镇痛药物的消耗。次要终点包括监测血流动力学参数、使用李克特量表评估患者和医生的满意度、使用辅助镇痛或镇静药物、复位尝试次数和在急诊科的时间。记录不良事件。统计分析将包括参数检验、多元线性回归和描述性统计。
该研究于 2021 年 11 月 3 日获得 Sud-Est IV 保护委员会的伦理批准(ANSM 于 2021 年 11 月 19 日通知)。研究结果将发表在科学文章中,并在国家和国际会议上进行交流。
ClinicalTrials.gov:NCT04992598;法国国家临床试验注册号:RCB:2021-A01382-39。